Hearscape
← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

OTO-413 by Otonomy

Also known as: OTO-413, BDNF formulation

Otonomy

Primary source
Company
Otonomy
Program Type
Therapeutic
Modality
Biologic
Stage
Phase 2
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
95%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States
Population
adult, noise-induced
Trial IDs
1
Mechanism

Sustained-exposure intratympanic formulation of BDNF intended to repair cochlear synapses and improve speech-in-noise performance.

Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
Notes

Important cochlear-synaptopathy/hidden-hearing-loss program; discontinued after higher-dose failure before Otonomy entered dissolution.

Evidence & Sources
3 structured sources
company
Supports: canonicalName, aliases, stage, status, notes
IDs: OTO-413
Open
company
Supports: mechanism, indications, route, populationTags
IDs: OTO-413
Open
company
Supports: company, allCompanies, notes
IDs: Otonomy
Open
Key Events
2022-10-13
Otonomy reported no clinically meaningful improvement for higher doses of OTO-413
Clinical Trials (1)
NCT04129775
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2